Literature DB >> 29751611

Purification and Characterization of Recombinant Botulinum Neurotoxin Serotype FA, Also Known as Serotype H.

Gavin Hackett1, Kevin Moore2, David Burgin3, Fraser Hornby4, Bryony Gray5, Mark Elliott6, Imran Mir7, Matthew Beard8.   

Abstract

We have purified and characterized recombinant botulinum neurotoxin serotype FA (BoNT/FA). This protein has also been named as a new serotype (serotype H), but the classification has been controversial. A lack of well-characterized, highly pure material has been a roadblock to study. Here we report purification and characterization of enzymatically active, and of inactive nontoxic, recombinant forms of BoNT/FA as tractable alternatives to purifying this neurotoxin from native Clostridium botulinum. BoNT/FA cleaves the same intracellular target proteins as BoNT/F1 and other F serotype BoNTs; the intracellular targets are vesicle associated membrane proteins (VAMP) 1, 2 and 3. BoNT/FA cleaves the same site in VAMP-2 as BoNT/F5, which is different from the cleavage site of other F serotype BoNTs. BoNT/FA has slower enzyme kinetics than BoNT/F1 in a cell-free protease assay and is less potent at inhibiting ex vivo nerve-stimulated skeletal muscle contraction. In contrast, BoNT/FA is more potent at inhibiting neurotransmitter release from cultured neurons.

Entities:  

Keywords:  SNARE proteins; bacterial toxin; botulinum toxin; neurotoxin; neurotransmitter release; protein purification; proteolytic enzyme; recombinant protein expression

Mesh:

Substances:

Year:  2018        PMID: 29751611      PMCID: PMC5983251          DOI: 10.3390/toxins10050195

Source DB:  PubMed          Journal:  Toxins (Basel)        ISSN: 2072-6651            Impact factor:   4.546


  59 in total

1.  Botulinum neurotoxin types B and E: purification, limited proteolysis by endoproteinase Glu-C and pepsin, and comparison of their identified cleaved sites relative to the three-dimensional structure of type A neurotoxin.

Authors:  S Prabakaran; W Tepp; B R DasGupta
Journal:  Toxicon       Date:  2001-10       Impact factor: 3.033

2.  Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity.

Authors:  Andreas Rummel
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

3.  Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5.

Authors:  Suzanne R Kalb; Jakub Baudys; Robert P Webb; Patrick Wright; Theresa J Smith; Leonard A Smith; Rafael Fernández; Brian H Raphael; Susan E Maslanka; James L Pirkle; John R Barr
Journal:  FEBS Lett       Date:  2011-12-09       Impact factor: 4.124

4.  Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics.

Authors:  Jiafu Wang; Jianghui Meng; Gary W Lawrence; Tomas H Zurawski; Astrid Sasse; MacDara O Bodeker; Marcella A Gilmore; Ester Fernández-Salas; Joseph Francis; Lance E Steward; K Roger Aoki; J Oliver Dolly
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

5.  Molecular characterization of a novel botulinum neurotoxin type H gene.

Authors:  Nir Dover; Jason R Barash; Karen K Hill; Gary Xie; Stephen S Arnon
Journal:  J Infect Dis       Date:  2013-10-07       Impact factor: 5.226

6.  A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.

Authors:  Jason R Barash; Stephen S Arnon
Journal:  J Infect Dis       Date:  2013-10-07       Impact factor: 5.226

7.  Molecular cloning of the gene encoding the mosaic neurotoxin, composed of parts of botulinum neurotoxin types C1 and D, and PCR detection of this gene from Clostridium botulinum type C organisms.

Authors:  K Moriishi; M Koura; N Fujii; Y Fujinaga; K Inoue; B Syuto; K Oguma
Journal:  Appl Environ Microbiol       Date:  1996-02       Impact factor: 4.792

8.  The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane.

Authors:  Lucia Muraro; Silvio Tosatto; Lisa Motterlini; Ornella Rossetto; Cesare Montecucco
Journal:  Biochem Biophys Res Commun       Date:  2009-01-20       Impact factor: 3.575

9.  Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin.

Authors:  G Schiavo; C C Shone; O Rossetto; F C Alexander; C Montecucco
Journal:  J Biol Chem       Date:  1993-06-05       Impact factor: 5.157

10.  Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.

Authors:  Jasmin Weisemann; Daniel Stern; Stefan Mahrhold; Brigitte G Dorner; Andreas Rummel
Journal:  Toxins (Basel)       Date:  2016-05-17       Impact factor: 4.546

View more
  9 in total

1.  Neuronal delivery of antibodies has therapeutic effects in animal models of botulism.

Authors:  Patrick M McNutt; Edwin J Vazquez-Cintron; Luis Tenezaca; Celinia A Ondeck; Kyle E Kelly; Mark Mangkhalakhili; James B Machamer; Christopher A Angeles; Elliot J Glotfelty; Jaclyn Cika; Cesar H Benjumea; Justin T Whitfield; Philip A Band; Charles B Shoemaker; Konstantin Ichtchenko
Journal:  Sci Transl Med       Date:  2021-01-06       Impact factor: 17.956

2.  Novel Native and Engineered Botulinum Neurotoxins.

Authors:  Lance Steward; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Handb Exp Pharmacol       Date:  2021

Review 3.  Engineering of Botulinum Neurotoxins for Biomedical Applications.

Authors:  Robert P Webb
Journal:  Toxins (Basel)       Date:  2018-06-06       Impact factor: 4.546

4.  Knockin mouse models demonstrate differential contributions of synaptotagmin-1 and -2 as receptors for botulinum neurotoxins.

Authors:  Hatim Thaker; Jie Zhang; Shin-Ichiro Miyashita; Vivian Cristofaro; SunHyun Park; Ali Hashemi Gheinani; Maryrose P Sullivan; Rosalyn M Adam; Min Dong
Journal:  PLoS Pathog       Date:  2021-10-18       Impact factor: 6.823

5.  Recombinant botulinum neurotoxin serotype A1 in vivo characterization.

Authors:  Cindy Périer; Vincent Martin; Sylvie Cornet; Christine Favre-Guilmard; Marie-Noelle Rocher; Julien Bindler; Stéphanie Wagner; Emile Andriambeloson; Brian Rudkin; Rudy Marty; Alban Vignaud; Matthew Beard; Stephane Lezmi; Mikhail Kalinichev
Journal:  Pharmacol Res Perspect       Date:  2021-10

Review 6.  Light Chain Diversity among the Botulinum Neurotoxins.

Authors:  Alexander P Gardner; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2018-07-02       Impact factor: 4.546

Review 7.  Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics.

Authors:  Jonathan R Davies; Sai Man Liu; K Ravi Acharya
Journal:  Toxins (Basel)       Date:  2018-10-20       Impact factor: 4.546

8.  Management of Anterocapitis and Anterocollis: A Novel Ultrasound Guided Approach Combined with Electromyography for Botulinum Toxin Injection of Longus Colli and Longus Capitis.

Authors:  Michael Farrell; Barbara I Karp; Panagiotis Kassavetis; William Berrigan; Simge Yonter; Debra Ehrlich; Katharine E Alter
Journal:  Toxins (Basel)       Date:  2020-09-30       Impact factor: 4.546

9.  New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency.

Authors:  David Burgin; Cindy Périer; Gavin Hackett; Mark Elliott; Daniel Kwan; Fraser Hornby; Imran Mir; Jacquie Maignel; Sai Man Liu; Matthew Beard
Journal:  Toxins (Basel)       Date:  2021-11-24       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.